The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Stepping down deliberately, and how to do it without losing progress — what changed since

This is a generated summary. It shows the 9 most-liked posts from a topic of 100, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
AN
a.nwosuTL217 Jun 2026 · edited#3

If you are stepping up mainly because the schedule says so rather than because the current dose has stopped doing what you wanted, that is worth noticing before rather than afterwards.

The number is defensible. The precision I gave it is not.

29 likes 1mo
CL
coldchain_liuTL3Regular23 Jun 2026#12

Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.

27 likes 1mo
ZN
z.nakamuraTL229 Jun 2026#25
d.tamm, post #2: Stepping down deliberately: the withdrawal trials show that stopping is followed by regain. The step-down literature is thinner. The conservative assumption is that stepping down is followed by some regain, with the magnitude unknown. The part I am sure of is shorter than the part I have written. Go to post

Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.

I have deliberately not rounded that, because the rounding is where the argument starts.

32 likes in reply to #2 29d
MC
m.coelhoTL23 Jul 2026#34

Appreciated. The plain phrasing does more work here than a longer post would.

31 likes 25d
RN
r.novakTL25 Jul 2026#39
sterile_table, post #30: Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose. Go to post

Dose and effect are not linear across the studied range for every compound in this class. Assuming a doubled dose gives a doubled effect is the reasoning error behind most disappointment.

30 likes in reply to #30 23d
CD
cohort_driftTL3Regular16 Jul 2026#68

I read post #64 twice before replying, because I had assumed the opposite.

Half steps are arithmetically simple and pharmacologically unstudied. They are not dangerous in any obvious way and they are also not what the evidence describes, and both halves of that should be said.

It is the sort of thing that seems obvious in retrospect and was not at the time.

26 likes 12d
GC
glossary_checkTL2Member18 Jul 2026#76

Fine by me. I had wanted a stronger conclusion and there is not one available.

32 likes 10d
B
BBramleyTL3Regular21 Jul 2026#85
s.beaulieu, post #63: That matches what I have seen, for whatever a single anecdote is worth. Go to post

Building on post #84 rather than restating it.

Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by real-world reports. The dose does not seem to stop working, but the longest trials are not indefinitely long.

That has held every time I have looked, which is not the same as always.

29 likes in reply to #63 7d
FC
f.chowdhuryTL226 Jul 2026#100

Confirming post #97 from a second method, which matters more than confirming it from a second person.

There is no published evidence about slower escalation because nobody studied it. That means the trials support not going faster and are silent on going slower, which is a different claim from "slower is fine".

I have separated what I observed from what I concluded, which does not always happen.

27 likes 2d

Read the full topic (100 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Revisiting: Holding a dose indefinitely: is there a documented downside?
The question in the title: Revisiting: Holding a dose indefinitely: is there a documented downside? I will give what I have already checked below so nobody repeats it. I have read the maintained page on this…
MVBVPKCC+26 30 4.5k 18mo
Reaching a dose and staying there for a year: a longitudinal note — does this still hold?
Asking directly, because I could not find a straight answer: Reaching a dose and staying there for a year: a longitudinal note — does this still hold? I have read the maintained page on this and I still have…
ISSSAKIR+35 39 547 11mo
Follow-up: Where the four-week escalation interval comes from, and what it is not
Where the four-week escalation interval comes from, and what it is not Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about four-week escalation…
TNOBJEPPMV+131 147 47k 18mo
Micro-titration: a disputed topic, argued properly — one year on
Posting this under the heading it deserves: Micro-titration: a disputed topic, argued properly — one year on Everything below is what sits behind that. Reading back through what has been written here about…
NSKRSICPAC+63 68 35k 1d
Follow-up: Why "dose equivalence" between different incretin analogues is a weak concept
Asking directly, because I could not find a straight answer: Why "dose equivalence" between different incretin analogues is a weak concept I have read the maintained page on this and I still have a gap, so I…
BWSANTIRSS+7 11 26k 9mo

Related topics — sharing the tags tirzepatide, semaglutide, titration

TopicParticipantsRepliesViewsActivity
Why semaglutide's albumin binding is the whole reason weekly dosing works
Asking directly, because I could not find a straight answer: Why semaglutide's albumin binding is the whole reason weekly dosing works Putting the numbers in the first post, because a question about a…
MMLIYR 2 63k 5mo
Peak-to-trough ratio at steady state for a weekly agent — the long version
Peak-to-trough ratio at steady state for a weekly agent — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about Peak-to-trough ratio,…
CTRSWAVUC+57 61 708 1d
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — setting out what I have, and where I think it stops being reliable. I have spent a fortnight trying to pin tirzepatide in type 2…
KHSCGIMYG+150 163 22k 11mo
Semaglutide in people without diabetes: what the evidence base looks like
Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of semaglutide…
GCSDNVMHN+2 6 18k 17mo
Clearance pathways and what renal impairment changes
Clearance pathways and what renal impairment changes Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of clearance pathways is wrong? I…
BAWADAKLS+11 15 43k 2mo